The biotechnology company Advancell, which does research into nanomedicine in Spain, has joined forces with the technological center Leitat, focused on industrial research, development and innovation. Together they have formed ReadyCell, a new company that is opening new markets in Europe and the United States, and which is facilitating the expansion of cell reagents.
A cell reagent is truly a revolution for pharmaceutical companies, as it allows resolving toxicity problems in very early phases of a drug’s production, and thereby saving on costs and time for companies.
Advancell contributes its technology and product licenses to the joint venture, while Leitat brings its manufacturing capacity: it develops the reagents in its facilities, integrating production in its own biotechnology and biomedicine equipment.
The agreement anticipates reinforcing the marketing structure of ReadyCell in order to increase sales of reagents in Europe and the United States. Advancell sells these products to the cosmetics, chemical and food industries, among others, and has seen annual sales rise on the order 35%.
Leitat thus increases its presence in the biomedicine sector, while Advancell takes steps to broaden its scientific discoveries. Today it has nanomedicine drugs in clinical trials to treat several diseases.